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Molecular Determinants of Metastatic
Transformation
by Sean E. Egan,*f Jim A. Wright,* and Arnold H.
Greenberg*t
In recent years, experimental systems have developed to analyze genetic and epigenetic regulation of
the metastatic phenotype. Numerous studies have uncovered a potent role for transforming oncogenes in
metastaticconversion. Inaddition, ithasbeenshownthatoncoproteinproductsoperate inadose-dependent
fashion. The continued expression of oncoproteins is required to induce and regulate metastatic dissem-
ination of tumor cells and, consequently, many of the signal transduction pathways that are controlled
by the oncogene products can regulate metastasis. Exogenous growth factors that act through these same
pathways also alter metastatic potential. Some primary and immortalized cells can be transformed by
oncogenes but remain completely benign and nonmetastatic. Malignant transformation can be achieved
in these cells through the cooperative interaction of specific oncogenes or loss of active suppression
regulated by recessive genetic determinants. Therefore, it is likely that tumor cells acquire the metastatic
phenotype through the cooperative interaction ofdominant and recessive genetic alterations. This model
is consistent with the correlative data accumulating in studies of human tumor specimens where more
malignant carcinomas often contain both activating mutations in oncogenes and either inactivating mu-
tations or loss of tumor-suppressor genes.
Introduction
The dissemination of cancer is a complex process re-
quiring many specialized characteristics. In order for a
tumor cell to metastasize, it must have the ability to
degrade extracellular matrix structures including base-
ment membranes, which line blood vessels and lym-
phatics. In addition, the metastatic cell must survive
hydrostatic pressure drops inthe microvasculature, im-
mune surveillance and, finally, possess the ability to
bind to endothelium at the secondary site, extravasate
out ofthe vessel, and form an autonomous lesion (1-3).
In the past, the metastatic cell has been viewed as
one whose phenotype is extremely unstable. It was
thought that through this instability, the large number
ofphenotypic characteristics could be acquired by a sin-
gle cell. Thus, the metastatic cascade was viewed as a
stochastic process involving a large number of gene
products. Highlymalignantcells areoftenaneuploidand
possess an unstable karyotype; however, it is difficult
to imagine that the large number ofproperties required
for metastasis could be achieved by a single cell ifthey
were truly independent events. The effects of this ge-
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nomic instability may be limited to relatively few genes
that can regulate the metastatic phenotype. In this al-
ternative model, instability facilitates tumor progres-
sion or evolution, but the genes are regulatory and not
a part ofthe ultimate metastatic phenotype.
There are numerous experiments that demonstrate
that many ofthese "metastatic properties" can be con-
trolled through the same signal transduction pathways
as growth and differentiation signals. For example,
platelet-derived growth factor (PDGF) can stimulate
protease secretion and motility as well as growth or
transformation (4). Work over the last 5 years on the
potential role ofoncogenes in metastatic dissemination
has provided evidence for this hypothesis (5-7).
In 1985, three groups demonstrated that transfor-
mation of NIH 3T3 cells by ras oncogenes resulted in
cell lines that expressed the full metastatic phenotype
in nude mice (8-10). This question was being indepen-
dently examined by several laboratories including our
own (7) and was confirmed and then extended by dem-
onstrating that introduction of ras into many types in-
cluding primary rat fibroblasts also induced the meta-
static phenotype (11,12). These experiments raised the
question of whether ras was directly regulating meta-
static behavior or was inducing a change in phenotypic
stability that would cause metastatic dissemination in
a ras-independent manner. In addition, it was not clear
if ras was inducing the metastatic phenotype through
the same mechanism that it could transform these cells.EGAN ET AL.
Direct Regulation of the Metastatic
Phenotype
Temperature-sensitive alleles ofoncogenes have been
isolated which demonstrated that the transformed phe-
notype was dependent on the continuous presence of
the oncoprotein. Inducible transformation systemshave
also been established with the mouse mammary tumor
virus (MMTV) long terminal repeat (LTR) directing
transcription of oncogenes such as v-ras (13). In this
case, the transformed phenotype was induced in atime-
and dose-dependent manner through addition of glu-
cocorticoids thatinitiated transcription ofthe oncogene.
The transformed phenotype was therefore dependent
not only on the continuous presence ofthe oncoprotein
but on the level of its expression.
Chambers and Wilson demonstrated that metastatic
properties of v-src-transformed cells were dependent
on the continuous presence of pp6O8r' activity using
NRK cells transformed by a temperature-sensitive v-
src gene in the chicken embryo assay (14). Our lab-
oratory has shown a correlation between ras gene ex-
pression andmetastatic potentialusingras-transformed
1OT1/2 fibroblasts. In addition, we found that induction
of an MMTV-LTR regulated v-H-ras gene in NIH 3T3
cells resulted in increased metastatic potential ofthese
cells (15). Thus, the dose-dependent regulation of the
transformed phenotype by oncogene products was also
observed for the metastatic phenotype.
Are the ras-Transformed and
Metastatic Phenotypes Genetically
Separable?
Muschel et al. transformed NIH 3T3 cells with either
normal cellular or viral H-ras (16). Cells transformed
by the viral gene were extremely metastatic, whereas
the proto-oncogene transformants did not metastasize
(16). In contrast, Bradley et al. reported that NIH 3T3
cells transformed by ras with one of several different
mutations including codons 12, 59, and 61, as well as
the overexpressed proto-oncogene, were all able to in-
duce the metastatic phenotype (17). These data can be
reconciled ifthe proto-oncogene is less potent at induc-
ing the metastatic phenotype than the oncogene. This
difference can be noted in transformation assays and
has nowbeendocumentedintwosystemsinvolvingmet-
astatic conversion (18,19).
Our laboratory has extended the range oftransform-
ing ras alleles that can induce the metastatic phenotype
in NIH 3T3 cells to include guanine nucleotide binding
mutantsinadditiontothose genesBradleyetal. studied
(17). In no case has a ras gene been found that can
transform NIH 3T3 cells without being able to induce
the metastatic phenotype in these cells. Thus far, dif-
ferences in the ability to induce metastasis has been
reflected at leastpartially indifferences intransforming
potential. This suggests that the mechanism through
which ras induces themetastatic phenotype in NIH 3T3
cells is likely the same mechanism by which it trans-
forms these cells. In addition, it has been found that
ras oncogenes canconvertmanydifferentcellsintomet-
astatic tumors (7,12). Although this information does
not shed any light on the signaling pathway p21 ras
uses, it does tell us that in malignant tumors in which
ras signalingis altered, this pathway mayberegulating
metastatic potential.
Other Oncogenes Can Induce the
Metastatic Phenotype
Although ras can induce and regulate the metastatic
behavior ofmany experimental cell systems, it is clear
that not all metastatic tumors contain activated ras
genes. Can other transforming oncogenes also induce
themetastaticphenotype? Inordertotestthisquestion,
we analyzed NIH 3T3 cells transformed by serine/thre-
onine kinase oncogenes such as mos and rafas well as
by three different classes oftyrosine kinase oncogenes
represented byfms, src, andfes. These genes were also
capable of inducing metastatic transformation of NIH
3T3 cells (20). In contrast, these cells transformed by
myc or p53 were completely nonmetastatic. As men-
tioned above, it had previously been shown that v-src-
transformed NRKcellsexpressedmetastaticproperties
in the chicken embryo CAM vein experimental metas-
tasisassaydevelopedbyChambersandco-workers(14).
In addition, Sadowski et al. reported that CCL39 fi-
broblasts transformed by v-fps were metastatic (21),
and Gao et al. found that v-mos transformation ofmink
lungcellsresultedinexpressionofthemetastaticpheno-
type (22).
The myc and p53 genes have also been shown to po-
tently regulate metastasis formation in other systems.
Bernards et al. have shown that enhanced expression
ofN-myc inthe rat neuroblastoma cell line B104results
in a transition from poorly metastatic to a highly in-
vasive, metastatic, and lethal tumor (23). In addition,
a mutant p53 gene converted mouse bladder carcinoma
cells to a highly metastatic tumor (24). Transformation
ofmanycellsbyanumberofstructurallydifferenttypes
ofsignaltransducinggeneproductsresultsinmetastatic
conversion. Not all oncogenes, however, can or will in-
duce the metastatic phenotype in a particular tumor
system. As mentioned previously, myc- and p53-trans-
formed NIH 3T3 cells are not metastatic (20). In ad-
dition, primary rat embryo fibroblasts transformed by
the combination of ElA type 2 and ras were not met-
astatic, in contrast to these cells transforned by ras
alone, which are highly malignant (11).
Growth Factor Regulation of the
Metastatic Phenotype
Many of the oncogenes encode proteins that are di-
rectlyinvolvedingrowthfactorsignaling. Theseinclude
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sis, which is the B-chain of PDGF, erb-B, which is the
receptor for EGF, andfms, which is the receptor for
CSF-1 (25). Since several oncogenes including the ty-
rosine kinase receptor fms were found to induce the
metastatic conversion of NIH 3T3 cells, it would seem
likely that signalingthrough these growth control path-
ways could normally regulate metastatic potential. We
have found that NIH 3T3 cells transformed through the
expression ofa secreted form ofbFGF are highly met-
astatic. In contrast, transient treatment ofras- or src-
transformed NIH 3T3 cells prior to intravenous injec-
tion resulted in a profound inhibition of lung colony or
experimental metastasis formation (unpublished data).
Therefore, growth factorregulation ofmetastatic prop-
erties can be either stimulatory orinhibitory depending
on the context of the signal. It has been previously
reported that stimulation ofB16 murine melanoma cells
by the tumor promoting phorbol ester 12-0-tetradeca-
noylphorbol acetate, which activates protein kinase C,
results in a stimulation ofexperimental metastasis for-
mation after IV injection (26). This phenomena also oc-
curs inras-transformed 1OT1/2 cells (unpublished data).
Consequently, several signal transducing pathways
within cells can regulate metastatic potential.
Another class ofsoluble regulators ofmetastatic dis-
semination exists, which, in many cases, may have pro-
found influence on the course of a tumor. Steroid hor-
mones such as estradiol are important mitogens for
manytumors. Inthecase ofbreastcancer, amajorform
of therapy involves blocking the estrogen signals that
reach tumortissue. This canbe achieved through ovari-
ectomy orthrough the administration ofanti-estrogens.
Estrogens have been found to not only influence the
mitotic status of the tumor, but work in experimental
systems suggests that estrogen actually stimulates dis-
semination of the tumor (27). Clinically important reg-
ulators of a tumor can operate through many growth
regulatingpathways. Insomecases, signaltransduction
may be altered within the tumor cell itself as a result
ofmutation ofagene product that operates on the path-
way, such as a growth factor or steroid receptor. In
other cases, a tumor may be receiving signals through
the same pathway from a nontumor source such as the
stroma with which the tumor is in contact, or from a
paracrine or endocrine source elsewhere in the body.
Cooperation between Dominant and
Recessive Oncogenes
Metastatic transformation in vitro by ras is limited
to some established cell lines and primary cells only
under special conditions. A single genetic lesion is nor-
mallyinsufficient notonlyforinductionofthemetastatic
phenotype but even for tumorigenic transformation.
For many years it has been known that tumor pro-
gression in vivo is a multistep process that usually oc-
curs over an extended period of time. In 1983 it was
shown that transformation ofprimary cells in vitro re-
quired the interaction of at least two cooperating on-
cogenes (28,29). The phenotypic response ofcells to an
oncogene like ras therefore, is dependent on the pres-
ence of other oncogenic lesions within the cell. In the
same way, metastatic conversion of NIH 3T3 cells by
numerous transforming oncogenes is likely dependent
on genetic and/or epigenetic alterations which led to in
vitro establishment of this aneuploid cell line. Muschel
et al. have reported that ras transformation ofanother
established murine cell line C127 does notresult in met-
astatic conversion (16). What factors determine
whether a particular oncogene can induce metastatic
conversion of a cell?
We have previouslyreported that ras transformation
of 1OT1/2 fibroblasts induces the metastatic phenotype
(15). In order to learn about the events that facilitate
susceptibility to metastatic conversion, these cells were
transfected with myc or ras or the sequential combi-
nation ofboth genes indialyzed calfserum. Underthese
conditions neither gene alone is transforming (30). The
combination of both genes resulted in potent transfor-
mation. Cell lines derived in this way were both an-
chorage independent and tumorigenic. In contrast to
1OT1/2 cells transformed by ras alone, most myc/ras
transformants were nonmetastatic. The myc gene had
made 1OT1/2 cells highly susceptible to ras-mediated
transformation but had not fully complemented ras in
allowing for metastatic conversion.
The ras gene alone can induce the full metastatic
phenotype when introduced in the presence ofa factor
present in fetal calf serum (15,30). Consequently, an
additional eventin cooperation with ras is necessary for
metastatic conversion. Introduction ofmyc into the ras
metastatic transformants does not suppress the meta-
static phenotype, therefore, metastasis is not inhibited
by myc. Finally, it was found that fusion of the non-
metastatic myc/ras transformants to the metastatic ras
transformants resulted in mostly nonmetastatic hy-
brids, indicating that the metastatic phenotype was re-
cessive. The cooperating eventinthis systemwas likely
to involve the loss of or inactivation of a recessive de-
terminant. It has also been shown in naturally derived
tumor cells that fusion ofmetastatic and nonmetastatic
cells resulted in the nonmetastatic hybrids (31). It is
likely, therefore, that the metastatic phenotype is
achieved through the cooperative interaction of both
dominant and recessive determinants.
Summary and Studies on Human
Tumors
An independent line of study has helped elucidate
events that are likely important in human tumor pro-
gression. In the last 3 years, severalteams ofresearch-
ers have uncovered provocative correlations between
specific genetic alterations and malignancy in neoplasia
ofthe breast, lung, and colon. Specific alterations have
been detected at several loci in human breast cancer.
The most striking finding, however, has been a corre-
lation between malignant behavior and amplification/
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overexpression ofthe HER2/neu (c-erb-B2) growth fac-
tor receptor (32-34). This gene product is apparently
wild-type but through overexpression renders tumor
tissuehighlysensitivetotheneuligand(35). Thestudies
described above may provide a mechanistic framework
for the interpretation of this clinical data. The neu li-
gand, whether produced by tumor or by nontumor tis-
sue, may be promoting not only growth but dissemi-
nation. The picture is likely not universal for all breast
cancer.
Many patients with metastatic breast cancer have
tumor cells that express low levels of HER2. In these
cases, other lesions such as amplifications ofthe growth
factorint-2gene, c-myc, and/oralterations ofthetumor-
suppressor genes p53 and Rb, which are often found
(36), may be important determinants of metastatic po-
tential. In human lung cancer, numerous different ge-
netic alterations have been found within single tumors
(37). In small cell as well as nonsmall cell carcinomas,
mutations have beenfound frequently in K-ras, Rb, and
p53. In addition, Rb and p53 and other loci on chro-
mosomes 3 and 11 are reduced to homozygosity, sug-
gesting that these loci are functioning as recessive de-
terminants of malignancy and that alterations at each
ofthe two alleles separately contribute tothemalignant
phenotype. In highly metastatic small cell lung cancer,
one of the c-, N-, or L-myc genes are often amplified.
Thesetumors areusually highlydisseminated, resistant
to therapy, and ultimately lethal.
Vogelstein and co-workers have recently presented
a model for tumor progression of colon carcinoma (38-
42). In this model, loss of tumor-suppressor genes on
chromosomes 5, 17 (p53), and 18 (DCC) cooperate with
mutational activation of K-ras and p53. The order in
which these events occur is variable, but the chromo-
some 5 and K-ras alterations often occurearly and prior
to frank carcinoma. In contrast, mutations at the p53
and DCC genes often occur at the transition to carci-
noma in situ or later. Since the ras gene activation is
often present in benign adenomas, it cannot be respon-
sible forinduction ofmetastasis formation. Onthe other
hand, these mutations have been observed to occur in
a different order, suggesting that each alteration may
becapableofcontributing aprogressive effecttotumors
at many different stages in the course of tumor evolu-
tion. If this is the case, then dissemination of the re-
sulting malignant tumor may be controlled through the
cooperative interaction ofthese and possibly as yet un-
identified genetic events. In other words, although one
specific genetic lesion maybe able to promotetransition
ofa tumorfromnonmetastatic to metastatic, the events
that preceded this ultimate change are all likely impor-
tant inthe maintenance andregulation ofthemetastatic
phenotype. Thus, the regulation of metastatic dissem-
inationmaybedependent onthecooperativeinteraction
of many specific genetic alterations that are present in
some malignant tumors. Ifall or most ofthe molecular
lesions are necessary for its dissemination, this would
predict that therapeutic approaches may need to only
reverse a single important genetic event.
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